A Lisbon traviata. Are clinicians ready to sing addio to monotherapy and libiamo to combinations?
- PMID: 11362792
A Lisbon traviata. Are clinicians ready to sing addio to monotherapy and libiamo to combinations?
Abstract
AIDS: The debate of monotherapy vs. combination therapy during the July 25th-27th Consensus Symposium on Combined Antiviral Therapy is discussed. Specific topics addressed at the Lisbon conference included whether the protease inhibitor, indinavir, could antagonize the effects of ZDV plus 3TC; synergy claimed with VX-478 and ZDV, ddI, and other reverse transcriptase inhibitors; a proposal that ablative therapy against HIV during the first weeks of infection could become a reasonable tactic when patients are diagnosed very early; a discussion of recent data suggesting that cross-resistance of HIV to several protease inhibitors is not an insurmountable problem and that convergent therapy with the drugs remains a possibility; and indications that HIV doubly resistant to 3TC and ZDV can emerge, at least when 3TC is started first and ZDV is added later.
Publication types
MeSH terms
Substances
LinkOut - more resources
Other Literature Sources
Medical